Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma

Bookmark and Share
Published: 1 Jun 2020
Views: 2488
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

Dr Saad Usmani talks to ecancer in an online interview about teclistamab for multiple myeloma, presented at the ASCO 2020 virtual meeting.

Teclistamab is an investigational bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors on T-cells in the treatment of patients with relapsed or refractory multiple myeloma.

Dr Usmani describes the results, as well as outlining the toxicities.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.